Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

February 07, 2025 07:54 ET | Source: Novo Nordisk A/S

Novo Nordisk A/S: Trading in Novo Nordisk shares by board members, executives and associated persons

Trading in Novo Nordisk shares by board members, executives and associated persons Bagsværd, Denmark, 7 February 2025 — This company announcement discloses the data of the transaction(s) made in Novo...
February 07, 2025 02:45 ET | Source: Novo Nordisk A/S

Novo Nordisk A/S: Once-weekly Mim8 is well-tolerated and efficacious in children living with haemophilia A with and without inhibitors

Phase 3 FRONTIER3 interim analysis data presented at EAHAD 2025 showed that 74.3% of children on once-weekly Mim8 prophylaxis experienced zero treated bleeds Bagsværd, Denmark, 7 February 2025 –...
February 06, 2025 04:12 ET | Source: Novo Nordisk A/S

Novo Nordisk A/S: Trading in Novo Nordisk shares by board members, executives and associated persons

Bagsværd, Denmark, 6 February 2025 — This company announcement discloses the data of the transaction(s) made in Novo Nordisk shares by the company’s board members, executives and their associated...
February 05, 2025 07:36 ET | Source: Novo Nordisk A/S

Novo Nordisk files annual report with the SEC

Bagsværd, Denmark, 5 February 2025 – Novo Nordisk A/S has filed its Annual Report 2024 on Form 20-F for the financial year 2024 with the US Securities and Exchange Commission (SEC), incorporating by...
February 05, 2025 01:30 ET | Source: Novo Nordisk A/S

Novo Nordisk's sales increased by 25% in Danish kroner and by 26% at constant exchange rates to DKK 290.4 billion in 2024

Bagsværd, 5 February 2025 - Financial report for the period 1 January 2024 to 31 December 2024 ...
February 04, 2025 07:57 ET | Source: Novo Nordisk A/S

Novo Nordisk A/S - share repurchase programme

Bagsværd, Denmark, 4 February 2025 – On 11 November 2024, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and...
January 27, 2025 08:05 ET | Source: Novo Nordisk A/S

Novo Nordisk A/S - share repurchase programme

Bagsværd, Denmark, 27 January 2025 – On 11 November 2024, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and...
January 24, 2025 05:19 ET | Source: Novo Nordisk A/S

Novo Nordisk successfully completes phase 1b/2a trial with subcutaneous amycretin in people with overweight or obesity

Bagsværd, Denmark, 24 January 2025 – Novo Nordisk today announced topline results from a phase 1b/2a clinical trial with amycretin, a unimolecular GLP-1 and amylin receptor agonist intended for once...
January 20, 2025 09:32 ET | Source: Novo Nordisk A/S

Novo Nordisk A/S - share repurchase programme

Bagsværd, Denmark, 20 January 2025 – On 11 November 2024, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and...
January 17, 2025 07:11 ET | Source: Novo Nordisk A/S

Novo Nordisk A/S: Semaglutide 7.2 mg s.c. achieved 20.7% weight loss in the STEP UP obesity trial, and 18.7% regardless of treatment adherence

Bagsværd, Denmark, 17 January 2025 – Novo Nordisk today announced headline results from STEP UP, a phase 3b trial in the global STEP programme. STEP UP is a 72-week efficacy and safety trial...